ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

ASH 2024 Summary: Menin Inhibitors in AML - FDA Approval and Highlig…

2024 ASH Annual Meeting Insights Hub

J. Zeidner

ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independe…

2024 ASH Annual Meeting Insights Hub

J. Watts

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

2024 ASH Annual Meeting Insights Hub

H. Fernandez

Revumenib for KMT2A+ R/R Acute Leukemias - Drug Overview and Clinica…

OncoPharm

J. Bossaer

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

Understanding the AML Disease State: Key Challenges and Advances

Cleveland Clinic Taussig Cancer Institute

M. Mustafa Ali

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Advancements in AML Management in 2024

Louisville Hematology Highlights

C. Lachowiez

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

Steroid-Refractory GVHD Updates

Roswell Park Comprehensive Cancer Center

S. Holtan

Long-Term Follow-Up of the VIALE-A Study: Survival Outcomes and Subg…

Walter Fiedler

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

Tandem 2025 Insights: PTCy-Based GVHD Prophylaxis After Mismatched U…

Insights from 2025 Tandem Annual Meeting

M. Al Malki

ASH 2025 Review: FLT3 Inhibitors in AML - Updates and Comparative In…

University of Colorado Division of Hematology

M. Angelos

Real-World Outcomes With Venetoclax and Azacitidine in AML Patients

Jad Othman

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet